Sunday, November 22, 2026
20 C
Bengaluru

Samit Mehta has been appointed Chief Operating Officer (COO) of Emcure Pharmaceuticals Ltd.

Samit Mehta brings extensive experience in healthcare leadership, business development, research and development, and strategic growth initiatives. In addition to his new role as COO of Emcure Pharmaceuticals, he also serves as Chief Executive Officer and Director on the Board of Gennova Biopharmaceuticals Ltd.

Over the years, Samit has played a significant role in strengthening Emcure’s presence across regulated markets, including the USA, Europe, and Canada. During his tenure as President – Research & Development at Emcure, he contributed to building a differentiated and diversified product portfolio through technology-driven innovation and strategic project execution.

He has been closely involved in advancing new product launches across high-growth therapeutic areas and enabling the organization’s expansion into emerging platforms. His leadership has supported Emcure’s focus on innovation, portfolio enhancement, and global market growth.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img